Estimates of economic rates of return for the U.S. pharmaceutical industry, 1976–1987

Estimation procedures are designed to consider features of publicly-available financial accounting information which allegedly compromise its use to estimate economic internal rates of return. These procedures, which focus on cashflows rather than conventional accounting income measures, are used to investigate the relative profitability of the U.S. pharamaceutical industry. Results indicate that pharmceutical returns exceed returns for comparable U.S. industrial firms during the period encompassed by the study. Differences for these comparisons are substantially less than what is implied by an uniformed use of accounting information, however. In particular, differences in implied internal rates of return of 2.1% to 3.8%, whereas differences in accounting rates of return are 4.0% to 5.6%. Results are robust for a wide variety of assumptions about industry growth rates and investment payout profiles, characteristics which potentially cause accounting-based return measures to differ from underlying internal rates of return.